GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2010

RedHill Biopharma to Market and Sell SCOLR Pharma’s Ondansetron Product

  • SCOLR Pharma granted RedHill Biopharma the worldwide rights to market and sell ondansetron tablet formulations based on SCOLR's controlled delivery technology.

    Under the terms of the licensing agreement, RedHill has agreed to make up-front and additional payments to SCOLR up to $600,000 based on achievement of certain regulatory milestones and the first commercial sale of the antinausea product and thereafter make payments to the company up to a maximum of $30 million based on the aggregate net sales by RedHill of the licensed product over a ten-year period.

    Ondansetron hydrochloride is the active ingredient in Zofran®, GlaxoSmithKline's drug to prevent chemotherapy and radiation related nausea and vomiting.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?